Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$331.94
+0.7%
$294.96
$205.87
$333.70
$43.28B0.23853,986 shs431,157 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$57.25
+0.1%
$57.88
$52.93
$94.85
$11.03B0.171.73 million shs1.38 million shs
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$56.44
$63.50
$11.52B1.152.05 million shsN/A
CureVac N.V. stock logo
CVAC
CureVac
$5.40
-0.1%
$4.46
$2.37
$5.72
$1.22B2.53786,138 shs751,012 shs
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+2.82%+8.72%+40.81%+33.48%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+3.77%+2.03%-5.00%-29.30%
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+12.33%
CureVac N.V. stock logo
CVAC
CureVac
0.00%+0.28%+21.51%+108.30%+72.92%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.2975 of 5 stars
2.44.00.04.33.92.50.6
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
4.946 of 5 stars
3.43.00.03.32.72.54.4
Catalent, Inc. stock logo
CTLT
Catalent
1.1114 of 5 stars
1.00.00.04.60.00.01.9
CureVac N.V. stock logo
CVAC
CureVac
4.6413 of 5 stars
4.15.00.04.91.00.01.3
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
1.2157 of 5 stars
0.00.00.03.20.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.79
Moderate Buy$340.002.43% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.75
Moderate Buy$93.6163.51% Upside
Catalent, Inc. stock logo
CTLT
Catalent
2.00
Hold$63.500.03% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8326.66% Upside
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HZNP, CVAC, BMRN, ALNY, and CTLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$97.00
6/30/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.00
6/26/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$320.00 ➝ $377.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/24/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.00
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/5/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$124.00 ➝ $104.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.25B19.25N/AN/A$0.52 per share638.35
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$2.85B3.85$3.23 per share17.71$29.69 per share1.93
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.09$0.86 per share6.24$3.36 per share1.61
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A372.97N/A-11.49%-510.31%-6.48%7/30/2025 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$426.86M$2.6921.2813.130.7917.76%11.34%8.95%8/4/2025 (Estimated)
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.86N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A

Latest HZNP, CVAC, BMRN, ALNY, and CTLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8.88
3.04
2.98
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.10
5.52
3.49
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Catalent, Inc. stock logo
CTLT
Catalent
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,230130.39 million128.43 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,040191.78 million190.15 millionOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable

Recent News About These Companies

Horizon Therapeutics Public Lim (HZNP)
PAC Profile: Horizon Therapeutics
5 Biotech Acquisition Targets To Accumulate In 2024
Horizon Therapeutics cut jobs in Deerfield after Amgen acquisition
Rule 17(e) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement – Horizon Therapeutics plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$331.94 +2.17 (+0.66%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$331.94 0.00 (0.00%)
As of 07/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$57.25 +0.08 (+0.14%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$57.24 -0.01 (-0.01%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.40 -0.01 (-0.09%)
As of 07/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Horizon Therapeutics Public stock logo

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.